Report: 2 Iscar execs could replace Buffett

Berkshire Hathaway chairman and CEO Warren Buffett could be succeeded by Iscar CFO Danny Goldman and CEO Jacob Harpaz.

April 23, 2012 01:26
Warren Buffet [file photo]

Warren Buffet 390 (R). (photo credit: Lucas Jackson / Reuters)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Iscar Ltd. CFO Danny Goldman and CEO Jacob Harpaz are candidates to succeed Berkshire Hathaway Inc. chairman and CEO Warren Buffett, according to Wall Street Journal columnist Jason Zweig.

Zweig based his assessment on Buffett’s annual letters to shareholders. Zweig ranked Goldman and Harpaz No. 14 and No. 15 as possible Buffett successors. They are far below the rankings of Ajit Jain, head of Berkshire’s reinsurance group, whom Buffett sited 102 times in his annual letters, and Geico CEO Tony Nicely, who was cited 60 times. Buffett has written more than 400,000 words in his annual letters since 1977.

Be the first to know - Join our Facebook page.

Buffett, 81, last week announced that he had stage 1 prostate cancer, the least malignant form of the disease, and that he would undergo chemotherapy.

He was optimistic and said he would continue running Berkshire Hathaway.

Nonetheless, the announcement raised concern about the day after Buffett and who his successor would be.

He has already said that Berkshire Hathaway’s board of directors has picked a successor, with two alternatives if necessary, but he has declined to mention any names.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection